The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.

@article{Arora2010TheLD,
  title={The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.},
  author={Mandeep Kumar Arora and K. Raghunandan Reddy and Pitchal Balakumar},
  journal={European journal of pharmacology},
  year={2010},
  volume={636 1-3},
  pages={137-44}
}
The present study investigated the combined effect of low doses of fenofibrate (PPAR-alpha agonist) and rosiglitazone (PPAR-gamma agonist) in diabetes-induced experimental nephropathy. Rats were administered streptozotocin (55 mg/kg i.p., once) to induce experimental diabetes mellitus. The development of diabetic nephropathy was assessed biochemically and histologically. In addition, the lipid profile and renal oxidative stress were assessed. The single administration of streptozotocin produced… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…